Proxygen

Executive Summary

Proxygen, an Austrian biotechnology company founded in 2018, is pioneering the discovery and development of molecular glue degraders, a novel small molecule modality targeting previously undruggable proteins. Based in Vienna, the company leverages its proprietary platform to systematically degrade disease-driving proteins, aiming to address a broad range of therapeutic areas with high unmet medical need. As a private entity, Proxygen has not disclosed its total funding or valuation, but its focus on molecular glue degraders—a rapidly advancing field in targeted protein degradation—positions it at the forefront of innovative drug discovery.

Upcoming Catalysts (preview)

• Q3 2026Series B Financing Round70% success
• Q1 2027IND Filing for Lead Molecular Glue Degrader Program40% success
• Q4 2026Partnership or Licensing Deal with Major Pharma30% success